Kuwana M, Kaburaki J, Okano Y, Inoko H, Tsuji K
Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
J Clin Invest. 1993 Sep;92(3):1296-301. doi: 10.1172/JCI116703.
HLA class II alleles were determined using the PCR-RFLP method in Japanese systemic sclerosis (scleroderma) patients with (n = 28) or without (n = 34) anti-topoisomerase I antibodies (anti-topo I). Either the DQB1*0601 or *0301 allele was recognized in all anti-topo I positive patients, compared with 44% of anti-topo I negative patients (P < 0.00001, relative risk [RR] > 41) or 58% of Japanese healthy control subjects (P < 0.00001, RR > 24). Tyrosine at position 26 in the second hypervariable region in the beta 1 domain of the DQB1 gene is common to these two alleles and is not present in any other known DQB1 alleles. We also examined immunoreactivities of anti-topo I positive sera to four different autoantigenic B cell epitopes of topo I molecule that were expressed as recombinant fusion proteins. One major B cell epitope, located within the region corresponding to amino acid residues 74-248, was perfectly associated with the amino acid sequence FLEDR at positions 67-71 in the beta 1 domain of the DRB gene. Two other epitopes, corresponding to 316-441 or 658-700, were associated with the serologically defined HLA-DR52 antigen. Patients with both FLEDR and DR52 demonstrated higher anti-topo I antibody titers. These results suggest that the HLA-DR and DQ genes together control the autoimmune response to topo I in systemic sclerosis.
采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法,对伴有(n = 28)或不伴有(n = 34)抗拓扑异构酶I抗体(抗拓扑异构酶I)的日本系统性硬化症(硬皮病)患者进行HLA II类等位基因检测。在所有抗拓扑异构酶I阳性患者中均检测到DQB10601或0301等位基因,相比之下,抗拓扑异构酶I阴性患者中该等位基因的检出率为44%(P < 0.00001,相对风险[RR] > 41),日本健康对照者中为58%(P < 0.00001,RR > 24)。DQB1基因β1结构域第二个高变区第26位的酪氨酸在这两个等位基因中是常见的,在任何其他已知的DQB1等位基因中均不存在。我们还检测了抗拓扑异构酶I阳性血清对拓扑异构酶I分子四个不同自身抗原性B细胞表位的免疫反应性,这些表位以重组融合蛋白形式表达。一个主要的B细胞表位位于对应于氨基酸残基74 - 248的区域内,与DRB基因β1结构域中第67 - 71位的氨基酸序列FLEDR完全相关。另外两个表位,对应于316 - 441或658 - 700,与血清学定义的HLA-DR52抗原相关。同时具有FLEDR和DR52的患者抗拓扑异构酶I抗体滴度更高。这些结果表明,HLA-DR和DQ基因共同控制系统性硬化症中针对拓扑异构酶I的自身免疫反应。